Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

NASDAQ:EOLS - Nasdaq - US30052C1071 - Common Stock

13.48  +2.97 (+28.26%)

After market: 13.94 +0.46 (+3.41%)

Fundamental Rating

3

Overall EOLS gets a fundamental rating of 3 out of 10. We evaluated EOLS against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EOLS have multiple concerns. EOLS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EOLS has reported negative net income.
EOLS had a negative operating cash flow in the past year.
EOLS had negative earnings in each of the past 5 years.
EOLS had a negative operating cash flow in each of the past 5 years.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.15%, EOLS is in the better half of the industry, outperforming 60.75% of the companies in the same industry.
EOLS has a Return On Equity of -941.60%. This is amonst the worse of the industry: EOLS underperforms 83.33% of its industry peers.
Industry RankSector Rank
ROA -24.15%
ROE -941.6%
ROIC N/A
ROA(3y)-30.87%
ROA(5y)-41.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

The Gross Margin of EOLS (69.94%) is better than 73.66% of its industry peers.
EOLS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for EOLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5YN/A
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EOLS has more shares outstanding than it did 1 year ago.
EOLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EOLS is higher compared to a year ago.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

EOLS has an Altman-Z score of -0.29. This is a bad value and indicates that EOLS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.29, EOLS perfoms like the industry average, outperforming 51.61% of the companies in the same industry.
A Debt/Equity ratio of 20.58 is on the high side and indicates that EOLS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 20.58, EOLS is doing worse than 86.56% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 20.58
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACCN/A
WACC11.16%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

EOLS has a Current Ratio of 2.47. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
EOLS has a Current ratio (2.47) which is in line with its industry peers.
EOLS has a Quick Ratio of 2.23. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
EOLS's Quick ratio of 2.23 is in line compared to the rest of the industry. EOLS outperforms 46.77% of its industry peers.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 2.23
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.94% over the past year.
The Revenue has grown by 34.42% in the past year. This is a very strong growth!
Measured over the past years, EOLS shows a very strong growth in Revenue. The Revenue has been growing by 52.93% on average per year.
EPS 1Y (TTM)35.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)34.42%
Revenue growth 3Y52.93%
Revenue growth 5YN/A
Sales Q2Q%22.12%

3.2 Future

EOLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.27% yearly.
Based on estimates for the next years, EOLS will show a very strong growth in Revenue. The Revenue will grow by 27.86% on average per year.
EPS Next Y53.52%
EPS Next 2Y48.93%
EPS Next 3Y47.28%
EPS Next 5Y45.27%
Revenue Next Year31.21%
Revenue Next 2Y31.82%
Revenue Next 3Y30.78%
Revenue Next 5Y27.86%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EOLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 99.74, EOLS can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, EOLS is valued a bit cheaper than the industry average as 72.58% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.44, EOLS is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 99.74
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
EOLS's earnings are expected to grow with 47.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.93%
EPS Next 3Y47.28%

More info and screens

0

5. Dividend

5.1 Amount

EOLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLUS INC

NASDAQ:EOLS (1/21/2025, 8:00:02 PM)

After market: 13.94 +0.46 (+3.41%)

13.48

+2.97 (+28.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners73.08%
Inst Owner Change-1.06%
Ins Owners1.97%
Ins Owner Change-0.23%
Market Cap853.55M
Analysts84.62
Price Target23.9 (77.3%)
Short Float %10.76%
Short Ratio8.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.15%
Min EPS beat(2)-60.88%
Max EPS beat(2)24.59%
EPS beat(4)2
Avg EPS beat(4)-23.98%
Min EPS beat(4)-75.59%
Max EPS beat(4)24.59%
EPS beat(8)6
Avg EPS beat(8)-9.24%
EPS beat(12)8
Avg EPS beat(12)-4.65%
EPS beat(16)11
Avg EPS beat(16)-3.59%
Revenue beat(2)0
Avg Revenue beat(2)-2.03%
Min Revenue beat(2)-3.78%
Max Revenue beat(2)-0.28%
Revenue beat(4)1
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-3.78%
Max Revenue beat(4)1.48%
Revenue beat(8)4
Avg Revenue beat(8)0.61%
Revenue beat(12)5
Avg Revenue beat(12)0.43%
Revenue beat(16)8
Avg Revenue beat(16)0.59%
PT rev (1m)0%
PT rev (3m)0.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 99.74
P/S 3.44
P/FCF N/A
P/OCF N/A
P/B 144.92
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)0.14
Fwd EY1%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS3.92
BVpS0.09
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.15%
ROE -941.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.94%
FCFM N/A
ROA(3y)-30.87%
ROA(5y)-41.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5YN/A
F-Score5
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 20.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.09%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 2.23
Altman-Z -0.29
F-Score5
WACC11.16%
ROIC/WACCN/A
Cap/Depr(3y)42.66%
Cap/Depr(5y)56.66%
Cap/Sales(3y)1.25%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y53.52%
EPS Next 2Y48.93%
EPS Next 3Y47.28%
EPS Next 5Y45.27%
Revenue 1Y (TTM)34.42%
Revenue growth 3Y52.93%
Revenue growth 5YN/A
Sales Q2Q%22.12%
Revenue Next Year31.21%
Revenue Next 2Y31.82%
Revenue Next 3Y30.78%
Revenue Next 5Y27.86%
EBIT growth 1Y28.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.87%
EBIT Next 3Y66.53%
EBIT Next 5Y63.64%
FCF growth 1Y70.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.18%
OCF growth 3YN/A
OCF growth 5YN/A